Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2-early breast cancer in the real-world setting

被引：0
|
作者：
Marques, Maud
Gambaro, Karen
Basik, Mark
Saad, Fred
Hassan, Saima Noor
Boudreau, Dominique
Vincent, Francois
St-Hilaire, Eve
Mackay, Helen
Abdelsalam, Mahmoud
Guillemette, Stephanie
Leite, Ricardo
Caron, Marc-Andre
Patel, Chandni
Batist, Gerald
机构：
[1] Exactis Innovat, Montreal, PQ, Canada
[2] Segal Canc Ctr, Montreal, PQ, Canada
[3] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[4] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[5] Hop St Sacrement, Quebec City, PQ, Canada
[6] Ctr Integr Univ Sante & Serv Sociaux, Mauricie Ctr Quebec, Trois Rivieres, PQ, Canada
[7] Ctr Oncol Leon Richard, Moncton, NB, Canada
[8] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[9] Moncton City Hosp, Moncton, NB, Canada
[10] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
[11] Novartis Canada, Toronto, ON, Canada
[12] Novartis Corp, Montreal, PQ, Canada
[13] Jewish Gen Hosp McGill, Segal Canc Ctr, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23303
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World Palbociclib Use in HR+/HER2-Advanced Breast Cancer in Canada: The IRIS Study
    Mycock, Katie
    Zhan, Lin
    Taylor-Stokes, Gavin
    Milligan, Gary
    Mitra, Debanjali
    CURRENT ONCOLOGY, 2021, 28 (01) : 678 - 688
  • [42] Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
    Joanne L. Blum
    Caroline DiCristo
    David Gordon
    Meghan S. Karuturi
    David Oubre
    Erin Jepsen
    Juan Cuevas
    Shailendra Lakhanpal
    Monica Z. Montelongo
    Zhe Zhang
    Joseph C. Cappelleri
    Yao Wang
    Debu Tripathy
    Breast Cancer Research and Treatment, 2024, 203 : 463 - 475
  • [43] Characterization of Immune Contexture in HR+/HER2-and Triple Negative Breast Cancer in a Real-world Cohort
    Chhibber, Aparna
    Dillon, Lloye M.
    Wojcik, John B.
    Dostal, Vishantie
    Lee, George
    Seifuddin, Fayaz
    Ely, Scott
    Stern, Mark D.
    Benson-Garnett, Charlie
    Roberts, Mustimbo
    Wu, Jenny
    CANCER RESEARCH, 2023, 83 (05)
  • [44] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer
    Cuyun Carter, Gebra
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Nash Smyth, Emily
    Mathur, Raina
    Cohen, Aaron B.
    Rasmussen, Erik
    Balakrishna, Shreya
    Morato Guimaraes, Claudia
    Rybowski, Sarah
    Seidman, Andrew D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) : 1179 - 1187
  • [45] Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2- Breast Cancer
    Valerio, Maria Rosaria
    Martorana, Federica
    Sano, Maria Vita
    Sambataro, Daniela
    Motta, Gianmarco
    Motta, Lucia
    Pavone, Giuliana
    Gebbia, Vittorio
    Scandurra, Giuseppa
    BIOMEDICINES, 2025, 13 (03)
  • [46] Real-world treatment patterns for HER2+and HR+/HER2-advanced breast cancer in county areas of China
    Ji, Y.
    Qu, H.
    Zhou, F.
    Ren, Y.
    Liang, W.
    Wang, J.
    Dai, G.
    Liu, M.
    Luo, J.
    Wu, Q.
    Tan, X.
    Meng, Q.
    He, W.
    Liu, W.
    Hu, G.
    Wang, J.
    Tang, H.
    Gao, J.
    Liu, H.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1424 - S1425
  • [47] Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2-metastatic breast cancer in the real-world setting
    Luhn, P.
    O'Hear, C.
    Ton, T. G.
    Sanglier, T.
    Hsieh, A.
    Oliveri, D.
    Chuo, J.
    Xiao, Y.
    Emens, L.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Multi-country study of the use of genomic assays in HR+, HER2-early breast cancer and characteristics of patients tested
    Brown, Jacqueline
    Williams, Rhys
    Rider, Alex
    Wild, Rosie
    Method, Michael
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2-Early Breast Cancer
    Klocker, Eva Valentina
    Egle, Daniel
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Gnant, Michael
    DRUGS, 2025, 85 (02) : 149 - 169
  • [50] A Multicountry Discrete Choice Experiment (DCE) to Understand Patients' Preferences for HR+/HER2-Early Breast Cancer (EBC) Treatments
    Harmer, V.
    Ammendolea, C.
    Ryan, M.
    Boyle, F.
    Werutsky, G.
    El Mouzain, D.
    Marshall, D.
    Thomas, C.
    Heidenreich, S.
    Lu, H.
    Payan, J. C. Mora
    Aubel, D.
    Danyliv, A.
    Pathak, P.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 47 - 47
12345